Glucagon-like peptide-1 receptor agonists (GLP-1 RA) were originally approved for the treatment of type 2 diabetes by enhancement of glucose-stimulated insulin secretion [4]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.